Fortrea Holdings Inc. FTRE NASDAQ · Healthcare · United States
$19.79 -2.03% -$0.41
Summary
29 / 100 · Bulios Score
What speaks for it
None of the indicators we track stands out on the positive side.
What to watch
- The company made a loss over the last 12 months.
- Operating profit does not even cover the interest on its debt.
- The share price is above the Bulios Fair Price.
- Revenue fell by 1.4% a year over the last 3 years.
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Score in detailPrice
Is it expensive?
Looks expensiveBy our assumptions the business is worth less than its shares cost today.
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
The company made a loss over the last 12 months, so there is no profit to set the price against.
Valuation in detailIs it growing?
SlowlyRevenue (USD)
Diluted EPS (USD)
- Analyst estimate
Revenue fell by 1.4% a year over the last 3 years. For the next fiscal year analysts expect revenue to fall by 1.7%.
Growth in detailDoes it make money?
PoorlyOver the last 12 months it made a loss of $68.7M.
Profitability in detailIs it financially healthy?
Debt is a burdenRepaying all its debt would take 9.0 years of free cash flow. Its debt is larger than its cash.
Financial health in detailDoes it pay a dividend?
NoIt pays no dividend.
Dividends in detailWhat do analysts expect?
Mildly positive- Buy 7
- Hold 5
- Sell 1
Today's price within the analysts' price targets
The average target of $23.44 is 18% above today's price. 54% of the analysts recommend buying.
Analysts in detailWhat does it earn on?
Fiscal year 2025By product
- Clinical Services Segment 100%
By region
- North America 47%
- Europe 31%
- Other Geographical Areas 21%
Clinical Services Segment brings in 100% of revenue.
Segments in detail